The global blood group typing market size was valued at USD 2.31 billion in 2025 and is projected to reach USD 5.59 billion by 2033, growing at a CAGR of 11.99% from 2026 to 2033. Market growth is driven by the rising burden of chronic diseases such as anemia, cancer, and blood disorders, which increases the need for frequent transfusions.
In addition, the growing number of surgical procedures, organ transplants, and trauma cases is further driving demand for accurate blood compatibility testing. The high burden of chronic diseases such as anemia, cancer, and hematological disorders is a significant driver of the blood group typing market, as these conditions often require frequent blood transfusions. For instance, according to a World Health Organization report published in 2025, anemia affects nearly 30% of women of reproductive age and around 40% of children under five globally, highlighting a substantial patient pool requiring transfusion support. Similarly, increasing cancer incidence and blood disorders such as thalassemia and sickle cell disease are contributing to repeated transfusion needs. This growing transfusion volume necessitates accurate ABO and Rh typing to ensure compatibility and prevent adverse reactions. Consequently, the rising prevalence of these chronic conditions is significantly accelerating demand for advanced blood group typing solutions worldwide.
The growing number of surgical procedures, organ transplants, and trauma cases is driving the demand for accurate blood compatibility testing, thereby supporting the growth of the blood group typing market. For instance, according to the World Health Organization (December 2023), around 1.2 million people die each year due to road traffic accidents, while many sustain non-fatal injuries and many require emergency transfusions. In addition, the number of organ transplant procedures has increased globally. According to an article published in PubMed in 2026, 173,727 solid organ transplants were performed worldwide in 2024, and these statistics were reported by the Global Observatory on Donation and Transplantation, an initiative of the WHO. These clinical situations require precise ABO and Rh typing and cross-matching to ensure patient safety. As the volume of surgeries and emergency care continues to rise, the need for reliable blood group typing solutions is also increasing.
Expanding blood donation programs and increasing transfusion volumes are contributing to the demand for routine blood group typing and compatibility testing. For instance, according to the statistics published by the World Health Organization in May 2025, over 118.5 million blood donations are collected globally each year, all of which require mandatory blood grouping and screening before use. In addition, advancements in molecular and automated typing technologies, including PCR-based genotyping, are improving accuracy and reducing turnaround time. The growing use of blood group typing in prenatal testing for diagnosing hemolytic disease of the newborn (HDN), along with stricter regulatory standards for transfusion safety, is further supporting the adoption of advanced typing solutions, thereby supporting overall market expansion. However, stringent approval processes and varying regulatory frameworks across regions can delay product launches and market entry.
This product will be delivered within 1-3 business days.
In addition, the growing number of surgical procedures, organ transplants, and trauma cases is further driving demand for accurate blood compatibility testing. The high burden of chronic diseases such as anemia, cancer, and hematological disorders is a significant driver of the blood group typing market, as these conditions often require frequent blood transfusions. For instance, according to a World Health Organization report published in 2025, anemia affects nearly 30% of women of reproductive age and around 40% of children under five globally, highlighting a substantial patient pool requiring transfusion support. Similarly, increasing cancer incidence and blood disorders such as thalassemia and sickle cell disease are contributing to repeated transfusion needs. This growing transfusion volume necessitates accurate ABO and Rh typing to ensure compatibility and prevent adverse reactions. Consequently, the rising prevalence of these chronic conditions is significantly accelerating demand for advanced blood group typing solutions worldwide.
The growing number of surgical procedures, organ transplants, and trauma cases is driving the demand for accurate blood compatibility testing, thereby supporting the growth of the blood group typing market. For instance, according to the World Health Organization (December 2023), around 1.2 million people die each year due to road traffic accidents, while many sustain non-fatal injuries and many require emergency transfusions. In addition, the number of organ transplant procedures has increased globally. According to an article published in PubMed in 2026, 173,727 solid organ transplants were performed worldwide in 2024, and these statistics were reported by the Global Observatory on Donation and Transplantation, an initiative of the WHO. These clinical situations require precise ABO and Rh typing and cross-matching to ensure patient safety. As the volume of surgeries and emergency care continues to rise, the need for reliable blood group typing solutions is also increasing.
Expanding blood donation programs and increasing transfusion volumes are contributing to the demand for routine blood group typing and compatibility testing. For instance, according to the statistics published by the World Health Organization in May 2025, over 118.5 million blood donations are collected globally each year, all of which require mandatory blood grouping and screening before use. In addition, advancements in molecular and automated typing technologies, including PCR-based genotyping, are improving accuracy and reducing turnaround time. The growing use of blood group typing in prenatal testing for diagnosing hemolytic disease of the newborn (HDN), along with stricter regulatory standards for transfusion safety, is further supporting the adoption of advanced typing solutions, thereby supporting overall market expansion. However, stringent approval processes and varying regulatory frameworks across regions can delay product launches and market entry.
Global Blood Group Typing Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global blood group typing market report based on product, techniques, test type, and region:Product Outlook (Revenue, USD Million, 2021-2033)
- Consumables
- Instruments
- Services
Techniques Outlook (Revenue, USD Million, 2021-2033)
- PCR-based and Microarray Techniques
- Assay-based Techniques
- Massively Parallel Sequencing Techniques
- Other Techniques
Test Type Outlook (Revenue, USD Million, 2021-2033)
- Antibody Screening
- HLA Typing
- Cross-matching Tests
- ABO Blood Tests
- Antigen Typing
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Blood Group Typing Market Variables, Trends, & Scope
Chapter 4. Blood Group Typing Market: Product Business Analysis
Chapter 5. Blood Group Typing Market: Techniques Business Analysis
Chapter 6. Blood Group Typing Market: Test Type Business Analysis
Chapter 7. Blood Group Typing Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Grifols S.A.
- Merck KGaA
- Bio-Rad Laboratories, Inc.
- Immucor, Inc
- Novacyt Group
- Danaher Corporation
- Agena Bioscience, Inc.
- Ortho Clinical Diagnostics
- Quotient, Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | April 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 2.31 Billion |
| Forecasted Market Value ( USD | $ 5.59 Billion |
| Compound Annual Growth Rate | 11.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
